GLP-1s offer significant promise to millions of Americans living with obesity, diabetes and/or cardiovascular disease, but their unprecedented demand and high price tags are creating challenging downstream impacts, including fluctuating supply, inconsistent clinical support, and runaway cost trajectory, said an Evernorth statement
The majority of adults were prescribed their first GLP-1 receptor agonist in 2017 or 2018
Danielle is a Registered Nurse with a BSN from the University of Alabama and a background that spans emergency medicine, travel nursing, outpatient surgery, cosmetic treatments, and IV hydration therapy
Hydration to support muscle recovery and joint health
Navigating the world of GLP-1 medications shouldn't be something you have to do alone